Document is current
Any future updates will be listed below
-
Authors
Kamitani, Fumika
Nishioka, Yuichi https://orcid.org/0000-0002-1956-3925
Koizumi, Miyuki
Nakajima, Hiroki
Kurematsu, Yukako
Okada, Sadanori
Kubo, Shinichiro
Myojin, Tomoya
Noda, Tatsuya
Imamura, Tomoaki
Takahashi, Yutaka
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (21K10474, 22H03355, 21K10451)
Nara Medical University Center for Diversity and Inclusion
the Ministry of Health, Labor and Welfare (Hypothalamo-hypophyseal Disorders and Endocrine Syndrome with Sexual Differentiation and Maturation grant)
- License Information
-
More Information
Article History
Received: 19 December 2022
Accepted: 30 October 2023
First Online: 7 November 2023
Competing interests
: FK received speaker fees from Dainippon Sumitomo, Sanofi, and Kyowa Kirin. YN received consultation fees from Novo Nordisk. SO received speaker fees from Ono; Mitsubishi Tanabe; Dainippon Sumitomo; Eli Lilly, Japan; Takeda; AstraZeneca; Novartis Pharmaceuticals; Novo Nordisk; Mochida Pharmaceutical; Kyowa Kirin; and Terumo. YT received consultant fees from Novo Nordisk, Otsuka, and Recordati and speaker fees from Novo Nordisk, Sumitomo Dainippon, Eli Lilly, Ono, Novartis, Nippon Boehringer Ingelheim, AstraZeneca, and Kyowa Kirin. The other authors declare that they have no conflicts of interest.
